Condition: Chronic Lymphocytic Leukemia (CLL) · Small Lymphocytic Lymphoma (SLL) · Sponsor: AstraZeneca
This study will evaluate the efficacy and safety of finite-duration acalabrutinib plus venetoclax therapy in patients with relapsed CLL or SLL, and have previously responded to first line (1L) cBTKi + BCL2i therapy (± obinutuzumab) and maintained a response for at least two years post-treatment.
This description comes directly from the study's public registry record.
AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com
Always discuss trial participation with your own doctor first.
| Research Site | Boston, Massachusetts, United States | Recruiting |
| Research Site | Charlotte, North Carolina, United States | Withdrawn |
| Research Site | Charlotte, North Carolina, United States | Recruiting |
| Research Site | Durham, North Carolina, United States | Recruiting |
| Research Site | Winston-Salem, North Carolina, United States | Recruiting |
| Research Site | Horn, Austria | Recruiting |
| Research Site | Goiânia, Brazil | Not Yet Recruiting |
| Research Site | Porto Alegre, Brazil | Not Yet Recruiting |
| Research Site | Porto Alegre, Brazil | Not Yet Recruiting |
| Research Site | São Paulo, Brazil | Not Yet Recruiting |
| Research Site | São Paulo, Brazil | Not Yet Recruiting |
| Research Site | Brno, Czechia | Not Yet Recruiting |
+ 24 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07024706